Nykode Therapeutics ASA (NYKD) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.057x

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has a cash flow conversion efficiency ratio of -0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.64 Million ≈ $-6.28 Million USD) by net assets (Nkr1.05 Billion ≈ $110.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Nykode Therapeutics ASA - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Nykode Therapeutics ASA debt and liabilities for a breakdown of total debt and financial obligations.

Nykode Therapeutics ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nykode Therapeutics ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Yuken India Limited NSE:YUKEN	0.020x
Currency Exchange International Corp TO:CXI	0.021x
Action Electronics Co Ltd TW:3024	-0.039x
Thuan Duc JSC VN:TDP	0.295x
Wielton S.A. WAR:WLT	-0.070x
Ramaco Resources Inc. NASDAQ:METCB	-0.003x
Edel SE & Co. KGaA F:EDL	0.113x
Crosswood PA:CROS	-0.020x

Annual Cash Flow Conversion Efficiency for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Nykode Therapeutics ASA market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr136.21 Million ≈ $14.33 Million	Nkr-51.22 Million ≈ $-5.39 Million	-0.376x	+33.35%
2023-12-31	Nkr171.26 Million ≈ $18.02 Million	Nkr-96.62 Million ≈ $-10.17 Million	-0.564x	-328.11%
2022-12-31	Nkr157.02 Million ≈ $16.52 Million	Nkr-20.69 Million ≈ $-2.18 Million	-0.132x	-2314.20%
2021-12-31	Nkr194.06 Million ≈ $20.42 Million	Nkr1.16 Million ≈ $121.54K	0.006x	-99.41%
2020-12-31	Nkr178.85 Million ≈ $18.82 Million	Nkr180.27 Million ≈ $18.97 Million	1.008x	+365.51%
2019-12-31	Nkr242.56 Million ≈ $25.52 Million	Nkr-92.08 Million ≈ $-9.69 Million	-0.380x	+15.31%
2018-12-31	Nkr140.07 Million ≈ $14.74 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.448x	-45.30%
2017-12-31	Nkr203.53 Million ≈ $21.42 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.308x	-347.33%
2016-12-31	Nkr23.19 Million ≈ $2.44 Million	Nkr-1.60 Million ≈ $-168.25K	-0.069x	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$110.82 Million

Nkr1.05 Billion NOK

Market Cap Rank

#18783 Global

#165 in Norway

Share Price

Nkr3.23

Change (1 day)

+5.74%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25